FDA to evaluate Avastin for deadly form of brain cancer

03/10/2009 | Forbes

An FDA panel is scheduled March 31 to review Genentech's application to promote Avastin as a treatment for a deadly form of brain cancer called glioblastoma multiforme. Avastin, which is approved to treat colon, breast and lung cancers, generated $2.69 billion in U.S. sales last year.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX